Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Zambon

Showing results (11-20 of 99) with videos related to

Pageof 10
Sort By:
Journal of the American College of Cardiology|February 4, 2021
Red Yeast Rice for Hypercholesterolemia: JACC Focus SeminarArrigo F G Cicero, Federica Fogacci, Alberto Zambon
Biochimica Et Biophysica Acta|October 12, 2011
The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotypeJohn D Brunzell, Alberto Zambon, Samir S Deeb
European Heart Journal. Cardiovascular Pharmacotherapy|October 29, 2020
The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?Alberto Zambon, Alberto Mello E Silva, Michel Farnier
Atherosclerosis|November 9, 2023
Lipid-lowering in diabetes: An updateAlan Chait, Robert H Eckel, Michal Vrablik, et al.
Diabetes Care|July 22, 2016
SGLT2 Inhibitors and the Diabetic KidneyPaola Fioretto, Alberto Zambon, Marco Rossato, et al.
Endocrinology and Metabolism Clinics of North America|August 13, 2022
New and Emerging Therapies for DyslipidemiaAlberto Zambon, Maurizio Averna, Laura D'Erasmo, et al.
Current Vascular Pharmacology|October 25, 2012
Statin treatment and carotid plaque composition: a review of clinical studiesMassimo Puato, Alberto Zambon, Elisabetta Faggin, et al.
Atherosclerosis|October 31, 2025
Not all fibrates are made equal: Learning from biology and clinical trialsAlberto Zambon, Bart Staels, Michel Farnier, et al.
Arquivos De Neuro-Psiquiatria|August 17, 2022
Myasthenia gravis in clinical practiceEduardo de Paula Estephan, José Pedro Soares Baima, Antonio Alberto Zambon
Arteriosclerosis, Thrombosis, and Vascular Biology|January 21, 2006
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidenceAlberto Zambon, Philippe Gervois, Paolo Pauletto, et al.
Pageof 10

Showing results (11-20 of 99) with videos related to

Sort By:
Pageof 10
Journal of the American College of Cardiology|February 4, 2021
Red Yeast Rice for Hypercholesterolemia: JACC Focus SeminarArrigo F G Cicero, Federica Fogacci, Alberto Zambon
Biochimica Et Biophysica Acta|October 12, 2011
The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotypeJohn D Brunzell, Alberto Zambon, Samir S Deeb
European Heart Journal. Cardiovascular Pharmacotherapy|October 29, 2020
The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?Alberto Zambon, Alberto Mello E Silva, Michel Farnier
Atherosclerosis|November 9, 2023
Lipid-lowering in diabetes: An updateAlan Chait, Robert H Eckel, Michal Vrablik, et al.
Diabetes Care|July 22, 2016
SGLT2 Inhibitors and the Diabetic KidneyPaola Fioretto, Alberto Zambon, Marco Rossato, et al.
Endocrinology and Metabolism Clinics of North America|August 13, 2022
New and Emerging Therapies for DyslipidemiaAlberto Zambon, Maurizio Averna, Laura D'Erasmo, et al.
Current Vascular Pharmacology|October 25, 2012
Statin treatment and carotid plaque composition: a review of clinical studiesMassimo Puato, Alberto Zambon, Elisabetta Faggin, et al.
Atherosclerosis|October 31, 2025
Not all fibrates are made equal: Learning from biology and clinical trialsAlberto Zambon, Bart Staels, Michel Farnier, et al.
Arquivos De Neuro-Psiquiatria|August 17, 2022
Myasthenia gravis in clinical practiceEduardo de Paula Estephan, José Pedro Soares Baima, Antonio Alberto Zambon
Arteriosclerosis, Thrombosis, and Vascular Biology|January 21, 2006
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidenceAlberto Zambon, Philippe Gervois, Paolo Pauletto, et al.
Pageof 10